Cost –effectiveness of BTK inhibitors vs bendamustine and rituximab in chronic lymphocytic leukemia patients
Future Oncology, Ahead of Print.
Source: Future Oncology - Category: Cancer & Oncology Authors: Jing Nie Huina Wu Qian Wu Qi Liu Lihui Liu Jiyong Wu Source Type: research
More News: Cancer & Oncology | Chronic Leukemia | Chronic Lymphocytic Leukemia | Leukemia | Rituxan | Treanda